药易购 reported revenue of ¥2.18B for the period ended 2026-06-30, +0.8% year on year. Net income was ¥-0.01B, a -0.6% net margin on a 9.2% gross margin. The largest revenue line is 药品(化药) at 94% of the total. Free cash flow for the period was ¥-0.07B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.18B | +0.8% |
| Gross profit | ¥0.20B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥-0.01B | — |
| Gross margin | 9.2% | Net margin -0.6% |
| Revenue Q/Q | -4.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药品(化药) | ¥2.04B | 93.6% |
| 其他主营业务 | ¥0.12B | 5.5% |
| 其他(补充) | ¥0.02B | 0.9% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.98B | 90.8% |
| R&D | ¥0.01B | 0.3% |
| SG&A | ¥0.19B | 8.5% |
| Tax & other | ¥0.00B | 0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥1.93B |
| Total liabilities | ¥1.15B |
| Shareholders' equity | ¥0.79B |
| Equity / assets | 40.7% |
| Operating cash flow | ¥-0.06B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.07B |
| Cash conversion (OCF / net income) | -52% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
信测标准 ・ 秋田微 ・ 南极光 ・ 创识科技 ・ 易瑞生物 ・ 春晖智控 ・ 曼卡龙 ・ 恒而达 ・ 德必集团 ・ 冠中生态 ・ 奥雅股份 ・ 德固特
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies